RecallRadar

FDA Drug recall D-0855-2020

Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc

On 2020-02-19 the FDA classified a Class II recall of Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc by Lupin Pharmaceuticals, citing failed Dissolution Specifications: Low out of specification results observed in dissolution test at six-month long-term stability study.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0855-2020
ClassificationClass II
Statusterminated
Initiated2020-02-12
Published2020-02-19
Last updated2026-09-13 11:52 UTC
CompanyLupin Pharmaceuticals
DistributionUS

Product

Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited Pithampur (M.P.)-454 775, INDIA, NDC 68180-248-06

Reason

Failed Dissolution Specifications: Low out of specification results observed in dissolution test at six-month long-term stability study.

Identifiers

ndc68180-246-06
ndc68180-249-06
ndc68180-249-09
ndc68180-249-02
ndc68180-247-06
ndc68180-247-09
ndc68180-248-06
code_infoLot #: H900330, exp. date 11/2020.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0855-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.